A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-19 and is reviewed periodically as new material appears.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Vampire: The Masquerade – Bloodlines is a 2004 action role-playing video game developed by Troika Games and published by Activision for Microsoft Windows. Set in White Wolf Publishing's World of Darkness, the game is based on White Wolf's role-playing game Vampire: The Masquerade and follows a human who is killed and revived as a fledgling vampire. The game depicts the fledgling's journey through early 21st-century Los Angeles to uncover the truth behind a recently discovered relic that heralds the end of all vampires. Bloodlines is presented from first-person and third-person perspectives. The player assigns their character to one of several vampire clans—each with unique powers—customizes their combat and dialog abilities, and progresses through Bloodlines using violent and nonviolent methods. The selection of clan affects how the player is perceived in the game world and which powers and abilities they possess; this opens up different avenues of exploration and methods of interacting with or manipulating other characters. The player can complete side missions away from the primary storyline by moving freely between the available hubs: Santa Monica, Hollywood, downtown Los Angeles, and Chinatown. Troika's 32-member team began developing Bloodlines in November 2001 as an indirect sequel to the previous year's Vampire: The Masquerade – Redemption. Troika used Valve's Source game engine, then in development, which was used for Valve's own Half-Life 2.
== Spikes to Stability: Trelagliptin Minimizes Glycemic Variability == Trelagliptin, a once-weekly DPP-4 inhibitor, helps manage glycemic variability (GV) in type 2 diabetes. It works by prolonging the activity of incretins (GLP-1 and GIP), which enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner. This action helps reduce [[[postprandial hyperglycemia]] and smooth out daily blood glucose fluctuations. Continuous glucose monitoring shows improved glycemic stability with lower glucose variability. Trelagliptin also lowers the risk of hypoglycemia due to its glucose-dependent effects. By reducing GV, it helps prevent damage to blood vessels. This ultimately lowers the risk of cardiovascular complications in diabetic patients.
Sichuan Corps Four mobile detachments Tibet Corps Three mobile detachments Tianjin Corps Yunnan Corps Three mobile detachments Xinjiang Corps Seven mobile detachments XPCC Corps (Not to be confused with the XPCC itself) Zhejiang Corps
Sources: en.wikipedia.org
Manuscripts of Pseudo-Apuleius's 5th-century work from the 10th and 11th centuries refer to the use of wild poppy Papaver agreste or Papaver rhoeas (identified as P. silvaticum) instead of P. somniferum for inducing sleep and relieving pain. The use of Paracelsus' laudanum was introduced to Western medicine in 1527, when Philippus Aureolus Theophrastus Bombastus von Hohenheim, better known by the name Paracelsus, claimed (dubiously) to have returned from wanderings in Arabia with a famous sword, within the pommel of which he kept "Stones of Immortality" compounded from opium thebaicum, citrus juice, and "quintessence of gold". The name "Paracelsus" was a pseudonym signifying him the equal or better of Aulus Cornelius Celsus, whose text, which described the use of opium or a similar preparation, had recently been translated and reintroduced to medieval Europe. The Canon of Medicine, the standard medical textbook that Paracelsus burned in a public bonfire three weeks after being appointed professor at the University of Basel, also described the use of opium, though many Latin translations were of poor quality. Laudanum was originally the 16th-century term for a medicine associated with a particular physician that was widely well-regarded, but became standardized as "tincture of opium", a solution of opium in ethanol, which Paracelsus has been credited with developing.
== Anatomy == The blood–brain barrier is formed by special tight junctions between endothelial cells lining brain blood vessels. Blood vessels of all tissues contain this monolayer of endothelial cells, however only brain endothelial cells have tight junctions preventing passive diffusion of most substances into the brain tissue. The structure of these tight junctions was first determined in the 1960s by Tom Reese, Morris Kranovsky, and Milton Brightman. Furthermore, astrocytic "end feet", the terminal regions of the astrocytic processes, surround the outside of brain capillary endothelial cells". The astrocytes are glial cells restricted to the brain and spinal cord and help maintain blood-brain barrier properties in brain endothelial cells.
Lee Hsien Loong's tenure included the 2008 financial crisis, the resolution of a dispute over land ownership at Tanjong Pagar railway station between Singapore and Malaysia, the introduction of the two integrated resorts (IRs) located at the Marina Bay Sands and Resorts World Sentosa as well as the COVID-19 pandemic. The PAP experienced its worst electoral performance in 2011, securing only 60% of the vote. While this would be considered a landslide victory in many countries since it preserved the party's supermajority, it was regarded locally as a poor outcome, reflecting public debate over issues such as the high rates of immigration and the rising cost of living. On 23 March 2015, Lee Kuan Yew died, and a one-week period of public mourning was observed nationwide. Subsequently, the PAP regained its dominance in Parliament through the September general election, receiving 69.9% of the popular vote, although this remained lower than the 2001 tally of 75.3% and the 1968 tally of 86.7%. The 2020 election held in July during COVID saw the PAP drop to 61% of the vote, while the Workers' Party (WP) took 10 of the 93 seats, including its leader Pritam Singh becoming the first de jure leader of the opposition since independence. On 15 May 2024, Lawrence Wong became Singapore's fourth prime minister and the first born after independence. Wong's first electoral test came at the 2025 election, which saw the PAP winning 65.5% of the vote and 87 out of 97 seats in Parliament; the WP retained their 10 seats.
Lung disease: Lung cancer Interstitial lung disease most commonly idiopathic pulmonary fibrosis Complicated tuberculosis Suppurative lung disease: lung abscess, empyema, bronchiectasis, cystic fibrosis Mesothelioma of the pleura Sarcoidosis Heart disease: Any disease featuring chronic hypoxia Cyanotic heart defect (most common cardiac cause) Infective endocarditis Atrial myxoma (benign tumor) Arteriovenous fistula or malformation Gastrointestinal and hepatobiliary: Malabsorption Crohn's disease and ulcerative colitis Cirrhosis, especially in primary biliary cholangitis Hepatopulmonary syndrome, a complication of cirrhosis Others: Graves' disease (autoimmune hyperthyroidism) – in this case, it is known as thyroid acropachy Familial and hereditary clubbing and "pseudoclubbing" (people of African descent often have what appears to be clubbing) Vascular anomalies of the affected arm such as an axillary artery aneurysm (in unilateral clubbing) Primary hypertrophic osteoarthropathy Nail clubbing is not specific to chronic obstructive pulmonary disease (COPD). Therefore, in patients with COPD and significant degrees of clubbing, a search for signs of bronchogenic carcinoma (or other causes of clubbing) might still be indicated.
Sources: en.wikipedia.org
==== Princes of the Royal Secret ==== In April 1818, a member of the Grand Orient de France named Louis de Clouet, who went by the Masonic codename d'Obernay, established a Grand Consistory of the Scottish Rite in Havana, Principes del Real Secreto (English: Princes of the Royal Secret). D'Obernay authorized the Grand Consistory to establish Lodges, chapters, and councils. He also authorized it to confer the 32nd Degree. The Grand Orient of France further authorized this work under the charter of the Grand Consistory dated April 7, 1819. Exactly how many Lodges were merged to create Principes del Real Secreto is debated. However, D'Obernay and this Grand Consistory did create several lodges, including L'Humanite, and La Constante Sophie, which received its charter directly from the Grand Orient of France. The Blue Lodges of the Grand Consistory were formed under the Gran Oriente Simbolico de la Nueva Thebaida (English: Symbolic Grand Orient of New Thebes), which was also known as the Gran Oriente Simbolico de la Isla de Cuba (English: Symbolic Grand Orient of the Island of Cuba). When the Grand Consistory was established, the Grand Orient of France relinquished their authority, handing it over to the National Grand Oriente of Spain. However, because the Grand Orient of Spain was bifurcated politically, the Cubans rejected its authority, preferring to remain autochthonous, instead of finding themselves on either side of the mainland Spanish divisions.
== History == Residency as an opportunity for advanced training in a medical or surgical specialty evolved in the late 19th century from brief and informal programs for extra training in a special area of interest. The first formal residency programs were established by William Osler and William Stewart Halsted at Johns Hopkins Hospital in Baltimore. Residencies elsewhere then became formalized and institutionalized for the principal specialties in the early 20th century. But even mid-century, residency was not seen as necessary for general practice and only a minority of primary care physicians participated. The expansion of medical residencies in the United States experienced a significant surge following World War II. In the post-war landscape, the demand for skilled physicians escalated, necessitating a robust training infrastructure. The G.I. Bill, a landmark piece of legislation, played a pivotal role in fueling this expansion by providing educational benefits to returning veterans, including those pursuing medical careers. The increased financial support facilitated a surge in medical school enrollments, spurring the need for expanded residency programs to accommodate the growing pool of aspiring physicians. This period witnessed the establishment of numerous new residency positions across various specialties. In 1940 there were approximately 6,000 residency positions available, but by 1970 the available spots had increased to more than 40,000. At the same time, the daily operation of the hospital increasingly relied on medical residents.
== Medical uses == Z-drugs are used for the short-term treatment of insomnia where difficulty with sleep initiation or sleep maintenance are prominent symptoms. Long-term use is not recommended, as tolerance, dependence, and addiction can occur. Z-drugs decrease sleep latency by 10 to 20 minutes. However, no Z-drug has shown clinically significant increase in total sleep time which is defined as at least 30 minutes. Tolerance develops within days to weeks. The risk of developing tolerance with Z-drugs is comparable to benzodiazepines. Z-drugs are recommended to be taken at the lowest effective dose, with a duration of 2–3 weeks, for short-term insomnia. Use of Z-drugs more than 4 weeks is not recommended. Caution must be taken when Z-drugs are used in conjunction with benzodiazepines, sedatives, alcohol or other drugs affecting the central nervous system. Cognitive behavioral therapy has been found to be superior to Z-drugs in the treatment of insomnia and has been found to have lasting effects on sleep quality for at least a year after therapy. A 2004 meta-analysis of randomised controlled clinical trials that compared benzodiazepines to Z-drugs found few clear and consistent differences between zopiclone and the benzodiazepines in sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia, and daytime alertness.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.